Vor Bio Awards Stock Options, RSUs to 10 New Hires as Inducements

Vor Bio granted stock options for 61,050 shares and restricted stock units for 12,900 shares to ten newly hired employees on June 1, 2026. The Compensation Committee of the Board of Directors approved both awards under the Vor Biopharma Inc. 2023 Inducement Plan.

57 per share, equal to the closing price of Vor Bio common stock on the grant date. They vest over four years, with 25 percent becoming exercisable after twelve months and the balance vesting monthly over the next thirty-six months, provided the recipients remain employed.

The RSUs also vest over four years, with 25 percent vesting after twelve months and the remainder vesting quarterly over the following thirty-six months, again conditioned on continued employment.

Both the options and the RSUs are governed by the Inducement Plan and by separate award agreements. Vor Bio stated that the equity awards were made as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The company is a clinical-stage biotechnology firm focused on advancing telitacicept, a dual-target fusion protein, through Phase 3 development for autoimmune diseases.

Its common stock trades on Nasdaq under the symbol VOR. The announcement was issued via GlobeNewswire on June 1, 2026, from the company’s Boston headquarters.